Media OutReach

DFI Retail Group Holdings Limited Half-Year Results For The Six Months Ended 30 June 2025 And Announcement Of Special Dividend

Published

5 months ago

22/07/2025

Media Outreach

Highlights

39% underlying earnings growth
Increased contributions from associates, Health & Beauty and Food
Health & Beauty delivered strong like-for-like (LFL) sales growth of 4%
Portfolio simplification continues with the announced divestment of Singapore Food business and sale of minority stake in Robinsons Retail
Proceeds from Yonghui and Robinsons Retail divestments strengthen balance sheet to a net cash position of US$442 million
Raised full-year underlying profit guidance to be between US$250 million and US$270 million
Declared special dividend of US¢44.30 per share in addition to interim dividend of US¢3.50

HONG KONG SAR – Media OutReach Newswire – 22 July 2025 – “We are pleased to report strong first-half underlying profit growth to US$105 million, supported by improved Health & Beauty and Food profitability, higher contribution from associates, and a stabilising revenue growth trend. Our ongoing portfolio evolution enables us to prioritise capital on high-margin businesses and growth initiatives, while providing strategic flexibility for inorganic opportunities. As a result of our strategic progress, we are pleased to announce a special dividend of US¢44.30 per share – the first in 18 years – returning a total of US$647 million to shareholders, including the regular interim dividend. These decisions underscore our confidence in DFI’s long-term growth strategy and commitment to shareholder returns.”

Scott Price
Group Chief Executive

OVERVIEW

The Group continued to demonstrate strong business resilience by effectively executing its strategic and margin expansion initiatives. Despite the continued shift towards value by consumers, LFL subsidiary sales for the first half of 2025 remained largely stable compared to the same period last year, excluding the impact of a significant cigarette tax increase in Hong Kong and the divestment of Hero Supermarket business in Indonesia in 2024. LFL subsidiary sales have demonstrated a steady recovery with a return to moderate growth in the second quarter of 2025.

Significant progress has been made in the Group’s strategic pivot from a portfolio investor to an operating company centred on five key deliverables:

Retail excellence: Delivering a best-in-class customer proposition
Customer access: Strategically expanding store network
Omnichannel and data ecosystem: Powering e-commerce and retail media with data-driven insights
Lean and agile operations: Streamlining business for more efficient decision making
Evolving portfolio: Prioritising capital returns and shareholder value

The Group continues to reinvest in pricing to deliver a stronger customer value proposition while resetting our sourcing strategy to expand gross profit. Reduction in financing costs and higher underlying profit from associates contributed to a 39% increase in underlying profit attributable to shareholders for the first half of 2025.

The Group continues to evolve its portfolio to enhance operational focus and enable more efficient capital allocation, supporting subsidiary business growth both organically and inorganically should shareholder accretive opportunities arise. During the reporting period, the Group completed the divestment of minority stakes in both Yonghui and Robinsons Retail, generating total gross proceeds of approximately US$900 million. Additionally, the Group announced the divestment of its Singapore Food business for approximately US$93 million in cash consideration.

As a result of this strategic progress, the Board has approved a special dividend of US¢44.30 per share, equivalent to US$600 million in total payment. Concurrently, the Group declared an interim dividend of US¢3.50 per share, in line with the prior comparable period. These decisions underscore the Group’s confidence in its long-term growth strategy and its commitment to creating value for its shareholders.

OPERATING PERFORMANCE

Overall

Total revenue from subsidiaries for the first half of 2025 was US$4.4 billion, up 0.3% year-on-year on a LFL basis, excluding the impact of a significant cigarette tax increase in Hong Kong and the divestment of the Hero Supermarket business in Indonesia in 2024. Strong sales growth in the Health & Beauty division was offset by lower contributions from other segments. Total revenue, which includes 100% of associates and joint ventures, was US$8.2 billion. Excluding the impact of the minority stake divestment in Yonghui completed at the end of February 2025, as well as the additional two months of sales contribution from Robinsons Retail following the stake disposal at the end of May 2025, total revenue increased by approximately 1%.

Total underlying profit attributable to shareholders for the first half of 2025 reached US$105 million, representing a year-on-year increase of 39%, primarily driven by improved performance in associates. Underlying profit from subsidiaries was US$75 million, reflecting a 3% year-on-year increase. Strong performance in the Health & Beauty and Food divisions was partially offset by lower profitability in Convenience as a result of the cigarette tax impact, and higher selling, general and administrative expenses[1] primarily due to a one-time reversal of long-term incentive accruals in 2024 related to executive departures. After accounting for the divestment of Yonghui, underlying profit from associates was US$30 million, an improvement from US$3 million from the prior comparable period, supported by higher contributions from both Maxim’s and Robinsons Retail.

Free cash flow for the period was a net inflow of US$89 million, compared with US$61 million in the first half of 2024. As at 30 June 2025, the Group’s net cash was US$442 million, compared to US$468 million net debt at 31 December 2024.

Subsidiaries

Sales for the Health & Beauty division were US$1.3 billion, up 4% year-on-year on a LFL basis, underscoring the strengthening brand equity of Mannings and Guardian as trusted advisors in health and wellness. Mannings Hong Kong delivered strong LFL sales growth of 6%, driven by growing basket size as the team continued to enhance assortment in key wellness categories, including supplements and derma skin care. Solid LFL sales performance of Guardian was supported by basket size increases across key Southeast Asian markets and improved promotional efficiency, particularly in Indonesia. Integrating the Own Brand team across Food and Health & Beauty drove stronger product relevance and cost efficiency, resulting in improved sales and profit productivity per SKU. Overall, divisional profit grew 8% to US$109 million on a LFL basis¹.

Total Convenience sales were US$1.1 billion, down 4% year-on-year on a LFL basis, primarily due to reduced volumes of lower-margin cigarette following tax increases in Hong Kong at the end of February 2024. Excluding cigarettes, overall LFL sales were down 1%. Hong Kong performance recovered in the second quarter, following the annualisation of the tax effect and continued growth in higher-margin ready-to-eat (RTE) categories. Excluding cigarettes, LFL sales for the first half were in line with the prior comparable period. 7-Eleven Singapore reported LFL sales below the same period last year. South China reported robust sales growth due to network expansion but lower LFL sales given intensified subsidy initiatives from food delivery platforms. The team remains focused on driving footfall and sales by expanding the RTE offering, including a larger rollout of the Food Bar format to 375 stores by the end of this year. Despite a favourable sales mix shift towards higher-margin RTE products, profit for the division dropped by 18% year-on-year to US$38 million due to tough comparables in the first half of 2024 as a result of a one-off windfall gain from cigarette inventory purchased before tax increase. Excluding which, profit for the division was up 9% year-on-year.

Revenue for the Food division reduced marginally to US$1.5 billion, after excluding the impact of the divestment of the Hero Supermarket business last year. Sales resumed growth in the second quarter, supported by the Group’s focus on enhancing the value of consumers’ food baskets. In Hong Kong, investment in reduced pricing has resulted in a 2.5% increase in footfall in May and 3.4% in June, in addition to a consistent rise in items per basket. To further enhance its fresh and value proposition, the Wellcome team launched a partnership with Dingdong Limited (DDL), a leading Chinese online grocery platform, during the second quarter of 2025. The collaboration offers consumers a wider selection of fresh produce at more competitive prices. The team’s effort to strategically source the core basket will support both price reinvestment and continued net margin expansion in the coming years. Overall Food profit grew 14% year-on-year to US$24 million on a LFL basis¹.

Sales performance of the Home Furnishings division remained challenged due to intense competition and shifts in basket mix, mainly in Hong Kong and Indonesia while Taiwan demonstrated relative resilience. Effective cost control measures across markets supported a recovery in underlying profit for the first half of the year. The IKEA Hong Kong business is strengthening its value-driven omnichannel proposition by reinvesting in core product pricing, evolving seasonal food range and leveraging yuu data for more precise customer targeting. In Indonesia, the IKEA team remains focused on driving sales through an expanded digital presence and intensified marketing efforts.

Digital

During the first half of 2025, the Group continued to strengthen its digital presence with the launch of new online channels, including a 7-Eleven app in Singapore. Our expanded digital assets, quick commerce service with third-party platforms and data-driven personalised offerings create a seamless omnichannel shopping experience across physical and digital touchpoints, contributing to a growing e-commerce penetration of approximately 5%. Daily e-commerce order volume surpassed 96,000, reflecting an 85% year-on-year increase and a substantial improvement in profit contribution.

DFIQ, the Group’s retail media business, continues to gain strong momentum, completing over 160 targeted marketing campaigns in the first half of 2025, compared to 12 in the prior comparable period. The DFIQ team has successfully piloted in-store media in select Mannings stores in Hong Kong, as well as Guardian and 7-Eleven outlets in Singapore. This uniquely integrated online-to-offline retail media solution provides suppliers with an expanded reach, driving enhanced customer loyalty and conversion throughout the entire purchase journey.

Associates

The Group’s share of Maxim’s underlying profits was US$14 million for the first half of 2025, up from US$8 million in the same period last year, underpinned by continued cost optimisation and operational efficiency measures. Sales performance was largely stable year-on-year, with strong growth in Southeast Asia offset by weaker restaurant performance in Hong Kong and the Chinese mainland.

Underlying profit contribution from Robinsons Retail was US$18 million, an improvement of approximately US$9 million from the first half of 2024. This includes the impact of two additional months of contribution, amounting to approximately US$5 million, following the completion of the divestment at the end of May 2025.

The divestment of the Group’s stake in Yonghui was completed in February 2025.

RECENT BUSINESS DEVELOPMENTS

On 24 March 2025, the Group announced that it had entered into a definitive agreement with Macrovalue, a leading Southeast Asian retail group, with respect to the divestment of its Singapore Food business, which includes the Cold Storage, CS Fresh, Jason’s Deli and Giant brands, for a total cash consideration of SGD125 million or approximately US$93 million, subject to adjustments. The transaction is subject to closing conditions and is expected to be completed by the end of 2025.

On 30 May 2025, the Group announced and completed the divestment of its 22.2% stake, in Robinsons Retail Holdings, Inc., for a total cash consideration of PHP15.8 billion or approximately US$283 million. Following the completion of the transaction, the Group ceases to hold any interest in Robinsons Retail.

The above transactions reflect the Group’s strategic pivot from a portfolio investor to a focused operating company, enabling the Group to redeploy capital to support the growth of its subsidiary businesses with higher accretive returns.

OUTLOOK

The Group remains confident in its ability to navigate the evolving market landscape, supported by strategic initiatives aimed at driving market share gain and profit growth across all businesses. These initiatives include strengthening the value proposition, optimising assortment through data-driven insights, expanding omnichannel presence and accelerating monetisation of digital assets. With a more focused business portfolio and enhanced operational efficiency, the Group is committed to delivering sustained, profitable growth by balancing ongoing investments in businesses and areas with long-term strategic value, while also increasing returns for shareholders.

The Group restates its full-year organic revenue growth outlook to a range of 0.5% to 1.0% (from approximately 2%), reflecting broader economic uncertainty and a sharper-than-expected decline in cigarette sales. Despite a more cautious revenue outlook, the Group expects to deliver stronger profitability through enhanced operational efficiency and disciplined cost management. The Group, therefore, revises its full-year guidance of underlying profit attributable to shareholders to be between US$250 million and US$270 million (up from previously between US$230 million and US$270 million).

Scott Price
Group Chief Executive

[1] Own brand and e-commerce related costs are reclassified from selling, general and administrative expenses to the corresponding business segments beginning first half of 2024

Hashtag: #DFIRetailGroup#Guardian#Mannings#7-Eleven#ColdStorage#Giant#Wellcome#IKEA#yuu#Maxim’s

The issuer is solely responsible for the content of this announcement.

DFI Retail Group

DFI Retail Group (the Group) is a leading Asian retailer, driven by its purpose to ‘Sustainably Serve Asia for Generations with Everyday Moments’.

At 30 June 2025, the Group and its associates operated over 7,500 outlets, of which over 5,500 stores were operated by subsidiaries. The Group, together with its associates, employed over 83,000 people, with over 45,000 employed by subsidiaries. The Group had total annual revenue in 2024 of US$24.9 billion and reported revenue of US$8.9 billion.

DFI is dedicated to delivering quality, value and service to Asian consumers through a compelling retail experience supported by an extensive store network and highly efficient supply chains.

The Group including its associates operates a portfolio of well-known brands across five key divisions: health and beauty, convenience, food, home furnishings and restaurants. The principal brands are:

Health and Beauty
• Mannings on the Chinese mainland, Hong Kong and Macau S.A.R.; Guardian in Brunei, Indonesia, Malaysia, Singapore and Vietnam.

Convenience
• 7-Eleven in Hong Kong and Macau S.A.R., Singapore and Southern China.

Food
• Wellcome and Market Place in Hong Kong S.A.R.; Cold Storage and Giant in Singapore; Lucky in Cambodia.

Home Furnishings
• IKEA in Hong Kong and Macau S.A.R., Indonesia and Taiwan.

Restaurants
• Hong Kong Maxim’s group on the Chinese mainland, Hong Kong and Macau S.A.R., Cambodia, Laos, Malaysia, Singapore, Thailand and Vietnam.

The Group’s parent company, DFI Retail Group Holdings Limited, is incorporated in Bermuda and has a primary listing in the equity shares (transition) category of the London Stock Exchange, with secondary listings in Bermuda and Singapore. The Group’s businesses are managed from Hong Kong. DFI Retail Group is a member of the Jardine Matheson group.

Media OutReach

MIMO: The AI-Native Storage Species Enables Desktop Scale AI Clusters With NVIDIA DGX Spark

Published

15 hours ago

12/12/2025

Media Outreach

Engineered for the AI era, MIMO delivers breakthrough metrics: 400 GB/s bandwidth, 54 million IOPS, and 40–90 μs latency—all within a form factor comparable to a large suitcase.
MIMO serves as both a high-performance data hub for large-scale GPU clusters and a flexible edge deployment platform, extending seamlessly to desktop environments where it orchestrates workflows with various DGX Spark units based on NVIDIA’s GB10 Grace Blackwell superchip.
This architecture enables independent AI clusters supporting up to 16 computing nodes within constrained environments, managing the complete workflow from large-scale pre-training and fine-tuning to production inference—effectively democratizing enterprise-grade AI capabilities for labs, edge sites, and distributed teams.

SINGAPORE –

Professor Zhang Sheng from Tsinghua University Shenzhen International Graduate School expressed a more pragmatic view: “With this solution, we finally no longer have to rely on the university’s data center. Our current annual budget alone is enough to deploy an AI cluster within our lab that better fits our needs—this will significantly boost our research efficiency both technically and operationally. It’s truly fantastic news.”

Asia Debut Marks Industry Inflection Point

Earlier at the 8th China International Import Expo (CIIE), the solution’s core—the world’s first AI-native storage system MIMO—made its strategic Asian debut. Engineered for the AI era, MIMO delivers breakthrough metrics: 400 GB/s bandwidth, 54 million IOPS, and 40–90 μs latency—all within a form factor comparable to a large suitcase.

The platform’s defining Fast-Light-Edge proposition, delivered through its breakthrough architecture, cut through the exhibition noise, generating immediate and widespread attention. MIMO earned exclusive features in top-tier media including Hong Kong Ta Kung Pao and China Securities Journal, while its product demonstration videos gained rapid traction across leading digital channels.

Addressing Foundational Challenges: Technical Dialogues That Matter

During the exhibitions, technical leaders from the United States, Spain, Singapore, Colombia, the UAE (Dubai), India, Pakistan, and Hong Kong SAR engaged in substantive dialogues with Ridger’s Asia team, raising questions that revealed systemic industry gaps:

Architectural Transformation & Strategic Positioning
“Can MIMO fundamentally replace legacy storage architectures—traditional NAS, unified, distributed, and parallel file systems—to deliver accelerated parallel training and high-concurrency inference?”
“With such exceptional performance, would deploying MIMO for traditional enterprise applications represent strategic overinvestment or forward-looking infrastructure?”

Mobile Deployment & Borderless Operations
“MIMO’s suitcase-sized footprint suggests unprecedented mobility. Can it truly accompany research teams globally like standard equipment? How does it maintain operational continuity across jurisdictions? What’s the customs protocol for such ‘technical luggage’?”

Seamless Integration & Global Accessibility
“In scenarios with unnetworked AI servers, can MIMO rapidly establish dedicated training environments with true plug-and-play functionality?”
“Does MIMO integrate transparently with existing AI infrastructure and software stacks without requiring modifications?”
“Beyond Asia-Pacific, what’s the procurement pathway for MIMO? Which currencies and payment methods are accommodated?”

Architectural Breakthrough: Redefining What’s Possible

Addressing these operational realities, Ridger demonstrated MIMO’s system-level value—transcending its role as a storage device to become an architectural cornerstone. MIMO serves as both a high-performance data hub for large-scale GPU clusters and a flexible edge deployment platform, extending seamlessly to desktop environments where it orchestrates workflows with various DGX Spark units based on NVIDIA’s GB10 Grace Blackwell superchip.

Notably, eight global OEM partners—including Dell, HPE, Lenovo, xFusion, H3C, MSI, GIGABYTE, and Acer—have concurrently launched Spark versions based on NVIDIA’s GB10 Grace Blackwell superchip, creating a robust compatibility foundation for MIMO’s ecosystem integration.

This architecture enables independent AI clusters supporting up to 16 computing nodes within constrained environments, managing the complete workflow from large-scale pre-training and fine-tuning to production inference—effectively democratizing enterprise-grade AI capabilities for labs, edge sites, and distributed teams.

As Zhu Ting, an industry observer from Beijing, noted: “This represents the ‘IBM PC moment’ for AI infrastructure—transforming specialized capability into accessible utility.”

Market Validation Through Early Adoption

Market response has been decisive. Following the exhibitions, pioneering organizations across pathological image foundation model development, legal-tech innovation, industrial visual inspection, and naked-eye 3D content production have joined Ridger’s Early Access program, validating the architecture’s transformative potential in real-world operational contexts.

Global Rollout: Accelerating Accessibility

Responding to accelerating global demand, Ridger confirmed the imminent launch of the complete MIMO portfolio and optimized solution bundles for specific DGX Spark configurations through the Ridger Official Global Store. Designed as a frictionless procurement channel, the platform will support diverse payment options including multiple fiat currencies and cryptocurrencies—streamlining access to advanced AI infrastructure.

Organizations seeking deeper understanding of MIMO and its integrated lightweight AI solution with DGX Spark are invited to connect with Ridger team or its strategic partner, NVIDIA Elite Solution Partner SinoInfo.
Hashtag: #Technology #ESG #AI #GPU #Enterprise #Finance #Storage #Flash #Compute #DGX-Spark #NVIDIA #AI-Lab #GDS #NAS #AI-Native

https://ridger.tech/
https://www.linkedin.com/company/ridger/
https://www.youtube.com/@ridgertech

The issuer is solely responsible for the content of this announcement.

Ridger

Ridger is a global technology pioneer building next-generation computing & storage infrastructure for the AI era. Born in the East and operating worldwide, Ridger challenges conventional paths to create new technological paradigms.

The team unites seasoned experts from global storage leaders with visionary AI architects, all driven by a shared mission to democratize cutting-edge technology, rejects incremental improvements and hollow prestige, focusing exclusively on foundational breakthroughs that deliver tangible value and sustainable impact.

From architecture to implementation and from service to empowerment, Ridger provides end-to-end solutions that help clients worldwide ascend to their highest summits.

Media OutReach

Johnson & Johnson and Asia Pacific Patient Advocacy Group Leaders Unite to Strengthen Shared Decision-Making in Lung Cancer Care

Published

16 hours ago

12/12/2025

Media Outreach

Patient survey finds that those engaged in shared decision-making were 11 times more likely to report higher satisfaction with their treatments, with 90% of lung cancer patients in Japan wanting to play an active role in their treatment decisions[1]

J&J deepens its commitment to patient empowerment in Asia Pacific by launching J&J withMe, a new patient portal offering tailored patient resources, and co-driving market-specific initiatives with patient advocacy groups

SINGAPORE – Media OutReach Newswire – 11 December 2025 – Johnson & Johnson announced the next phase of The 3rd Opinion campaign across Asia Pacific, focused on championing shared decision-making between lung cancer patients and healthcare professionals through events and stakeholder engagements at ESMO Asia 2025 in Singapore.

At a Patient Reception on 6^th December 2025, 20 leaders from 17 patient advocacy groups from across Asia Pacific, Europe and the United States shared their support for the need to strengthen shared decision-making. On December 7, 2025, the ESMO Asia 2025 Symposium, ‘Advancing EGFRm NSCLC Treatment Through Shared Decision-Making’ highlighted the role of healthcare professionals not only in making sense of the data but also in helping patients and their families navigate complex decision-making.

“High prevalence in Asia of certain NSCLC mutations makes the choice of first-line therapy absolutely critical. Treatment decisions must balance clinical objectives with patient values — weighing disease biology, survival prospects, durable disease control and the tradeoffs of side effects. That’s why shared decision-making is essential: clinicians should present all appropriate treatment options, so the final choice is collaborative and aligned with each patient’s goals,” said Professor Zhu Zhengfei, Director of the Radiation Oncology Department, Fudan University Shanghai Cancer Center.

“When lung cancer patients are empowered to speak up and understand their options, they are more likely to continue the treatment and their dignity is preserved. Initiatives like ‘The 3rd Opinion’ are vital for fostering truly patient-centered partnerships between people living with cancer and their healthcare teams,” noted Ms. Liu Yiting, Marketing & Branding Director, China MeetHealth Mi-Jian Patient Community.

“The shared commitment validates what many people living with lung cancer have long expressed: shared decision making is essential. From our experience supporting patients, meaningful conversations with clinicians help acknowledge patients’ experiences, address their concerns, and preserving their hopes,” added Mr. Jung-Il Cho, Chairman of Korea Lung Cancer Patients Association.

Our commitment comes off the back of a recent patient survey revealing that 90% of Japanese lung cancer patients want to play an active role in their treatment decisions. The survey also found that shared decision-making, where physicians and patients jointly compare treatment options and decide together, is the strongest driver of treatment satisfaction.¹

To bridge the gap between patients’ desire to engage in shared decision making and their lack of practical support, J&J has launched “J&J withMe”, an online hub that equips lung cancer patients and caregivers with tailored toolkits and conversation guides to prepare for consultations and make informed, personalized treatment decisions.

Anthony Elgamal, Vice President of Oncology, Johnson & Johnson Innovative Medicine Asia Pacific said, “The 3rd Opinion truly puts patients at the center of care. As part of our deep commitment to address patients’ unmet needs, we will continue partnering with patient advocacy groups and healthcare professionals to help patients to find their voice and the moment when medical advice meets what truly matters to patients.”

In recognition of diverse cultural and clinical norms across Asia Pacific, J&J has also rolled out tailored market activations in collaboration with local patient advocacy groups:

Provision of patient resources such as the “Lung Cancer Book of Answers” in China, ‘Value of Time’ video for patients in Japan, and educational assets in India and Australia/New Zealand;
Digital and social media engagement featuring patients and creators discussing the importance of shared decision-making across Singapore, Malaysia, Philippines, Thailand, and Vietnam;
Event engagement via the establishment of a patient advisory board in India;
Corporate Social Responsibility program with a lung cancer patient group in Korea, bringing employees and patients together to better understand the disease burden of patients and strengthen emotional support for the patient community.

###

About the 3^rd Opinion

“The 3rd Opinion”, the patient’s own opinion, is a new term that sparks a social movement in the lung cancer treatment journey – designed to elevate the patient voice and empower individuals to take an active role in shaping their treatment plan. By prioritizing shared decision-making between patients and healthcare professionals, this collaborative approach ensures that treatment choices are aligned to each patient’s goals, preferences and circumstances. This results in more informed decisions, greater patient satisfaction, and the best possible outcomes.

About Non-Small Cell Lung Cancer

Worldwide, lung cancer is one of the most common cancers, with NSCLC making up 80 to 85 percent of all lung cancer cases.[1]^, [2] The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.[3] Among the most common driver mutations in NSCLC are alterations in EGFR, which is a receptor tyrosine kinase controlling cell growth and division.[4] EGFR mutations are present in 10 to 15 percent of Western patients with NSCLC with adenocarcinoma histology and occur in 40 to 50 percent of Asian patients.[5]^{, [6],[7],[8],[9],[10]}EGFR ex19del or EGFR L858R mutations are the most common EGFR mutations.[11] The five-year survival rate for all people with advanced NSCLC and EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs) is less than 20 percent.[12]^,[13] EGFR exon 20 insertion mutations are the third most prevalent activating EGFR mutation.[14] Patients with EGFR exon 20 insertion mutations have a real-world five-year overall survival (OS) of eight percent in the frontline setting, which is worse than patients with EGFR ex19del or L858R mutations, who have a real-world five-year OS of 19 percent.[15]By comparison, other common cancers, such as breast and prostate cancer have a 5-year real world OS of 90% and 97% respectively[16].

[1] Johnson & Johnson lung cancer patient quantitative survey conducted in Japan, 2025

[2] The World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed March 2025.

[3] American Cancer Society. What is Lung Cancer? https://www.cancer.org/content/cancer/en/cancer/lung-cancer/about/what-is.html. Accessed March 2025.

[4] Oxnard JR, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013 Feb;8(2):179-84. doi: 10.1097/JTO.0b013e3182779d18.

[5] Bauml JM, et al. Underdiagnosis of EGFR Exon 20 Insertion Mutation Variants: Estimates from NGS-based Real World Datasets. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.

[6] The World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed March 2025.

[7] American Cancer Society. What is Lung Cancer? https://www.cancer.org/content/cancer/en/cancer/lung-cancer/about/what-is.html. Accessed March 2025.

[8] Pennell NA, et al. A phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small cell lung cancer. J Clin Oncol. 37:97-104.

[9] Burnett H, et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.

[10] Zhang YL, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985-78993.

[11] Midha A, et al. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity. Am J Cancer Res. 2015;5(9):2892-2911.

[12] American Lung Association. EGFR and Lung Cancer. https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/symptoms-diagnosis/biomarker-testing/egfr. Accessed March 2025.

[13] Howlader N, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site.

[14] Lin JJ, et al. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol. 2016 Apr;11(4):556-65

[15] Arcila, M. et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013 Feb; 12(2):220-9.

[16] Girard N, et al. Comparative clinical outcomes for patients with NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.

[17] Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute, 2024.

Hashtag: #Johnson&Johnson

The issuer is solely responsible for the content of this announcement.

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com. Follow us at @JNJInnovMed.

Johnson & Johnson Innovative Medicine Asia Pacific, a division of Johnson & Johnson International (Singapore) Pte. Ltd is a Johnson & Johnson company.

Media OutReach

Skychakra Global Capital Strategy Upgrade: Advancing Cross-Border Listings and RWA Ecosystem

Published

1 day ago

11/12/2025

Media Outreach

HONG KONG SAR – Media OutReach Newswire – 11 December 2025 – Skychakra Group recently held a grand inauguration ceremony at the Hong Kong International Center, announcing the official acceleration of its globalization strategy. With a mission to “enhance individual energy, empower enterprise growth, and promote asset capitalization,” Skychakra simultaneously launched three major international initiatives: a cross-border listing incubation system, an RWA (Real World Assets) technology ecosystem, and the international upgrade of mind-body energy science, building a new economic ecosystem that spans technology, industry, and capital.

As a global hub for innovation and capital, Hong Kong serves as a significant gateway for the activation of Skychakra’s global strategy. This inauguration not only symbolizes the completion of the facility but also marks the comprehensive rollout of Skychakra’s international layout.

Official Launch of Cross-Border Listing Incubation Center

During the inauguration, Skychakra announced the establishment of a cross-border listing incubation center, led by a professional team qualified with SEC, PCAOB, and FINRA credentials, boasting over a hundred projects in cross-border listings. The service scope includes U.S. stocks, Hong Kong stocks, and SPACs. Unlike traditional investment banks and financial advisors, Skychakra offers a “full-link” service for enterprise capitalization, encompassing red-chip structure setup, financial and audit compliance, SEC and Hong Kong Stock Exchange filing guidance, dual-path IPO/SPAC design, market value management, enterprise internationalization guidance, and digital upgrades.

Originally planning to sign contracts for four companies at the conference, Skychakra exceeded expectations by signing 12, demonstrating its strong appeal and industry influence in cross-border listings and capital operations.

RWA Technology Ecosystem: Making Enterprise Assets Visible to the Financial System

Real World Assets (RWA) are becoming the core of global financial transformation. From BlackRock’s launch of tokenized funds to Hong Kong and Singapore incorporating RWA into financial infrastructure, RWAs are transitioning from concept to large-scale implementation. Skychakra emphasizes that small and medium-sized enterprises face common challenges such as lack of recognition for their assets within the financial system, difficulties in cross-border financing, and a lack of transparency in asset value.

The Skychakra RWA ecosystem will provide enterprises with: tokenizable asset identification, asset structuring and entitlement, on-chain mapping and minting, cross-border compliance design, global issuance and liquidity channels, and on-chain risk control and transparent tracking. The core value of RWA lies in reducing friction for enterprises in connecting to global capital, enhancing asset liquidity and valuation potential.

A Holistic Growth Model: “From People to Enterprises, From Enterprises to Capital”

Skychakra’s differentiated advantage stems from its foundational logic of “starting with people.” The Skychakra energy courses utilize scientific equipment to measure energy fields, emotional frequencies, and meridian states, assisting individuals in enhancing stability, insight, and decision-making abilities.

Based on this foundation, Skychakra constructs three major systems:

1. Enterprise Growth System: Enhancing organizational capabilities, introducing international business, and providing capital operation guidance.

2. Capitalization System: Building global financing capabilities through listings and RWA structures.

3. Asset Digitalization System: Making enterprise value quantifiable, verifiable, and tradable.

These three systems dynamically interact in a spiral structure, forming Skychakra’s unique full-link growth ecosystem.

Conclusion: Global Layout for Greater International Influence

The inauguration of Skychakra’s Hong Kong International Center signifies the official implementation of the group’s globalization strategy. Looking forward, the focus will be on Hong Kong as the core, with Asia as the main axis, while establishing deep collaborations with the North American and Middle Eastern markets. Through this global layout, Skychakra is creating a new organizational model that transcends regions, industries, and capital, enabling enterprises to achieve value flow in the global market and allowing more Asian companies to gain a stronger voice on the international stage.

Hashtag: #Skychakra

The issuer is solely responsible for the content of this announcement.